bi 655130
mAbexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02525679)
Timeline
Indications
Mechanism of action
- IL36 receptorINHIBITOR
IL36 receptor inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bi655130
- bi 655130
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05856526 | Phase 2/Phase 3 (Phase 3) | May 15, 2023 | Boehringer Ingelheim |
| NCT04390568 | Phase 1 | May 21, 2020 | Boehringer Ingelheim |
| NCT03123120 | Phase 2 | Jun 7, 2017 | Boehringer Ingelheim |
| NCT03135548 | Phase 2 | May 30, 2017 | Boehringer Ingelheim |
| NCT03100864 | Phase 2 | May 22, 2017 | Boehringer Ingelheim |
| NCT03123094 | Phase 1 | May 16, 2017 | Boehringer Ingelheim |
| NCT03100903 | Phase 1 | Apr 24, 2017 | Boehringer Ingelheim |
| NCT02978690 | Phase 1 | Dec 19, 2016 | Boehringer Ingelheim |
| NCT02852824 | Phase 1 | Aug 10, 2016 | Boehringer Ingelheim |
| NCT02525679 | Phase 1 | Sep 1, 2015 | Boehringer Ingelheim |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 10 | 10 | 3 | 2015 |
1 organizations
Page 1 / 1